Melittin and phospholipase A2-activating protein (PLAP) are known as efficient activators of secretory phospholipase A2(sPLA2) types I, II, and III when phospholipid liposomes are used as substrate. The present study demonstrates that both peptides can either inhibit or activate sPLA2 depending on the peptide/phospholipid ratio when erythrocyte membranes serve as a biologically relevant substrate. Low concentrations of melittin and PLAP were observed to inhibit sPLA2-triggered release of fatty acids from erythrocyte membranes. The inhibition was reversed at melittin concentrations above 1 microM. PLAP-induced inhibition of sPLA2 persisted steadily throughout the used concentration range (0-150 nM). The two peptides induced a dose-dependent activation of sPLA2 at low concentrations, followed by inhibition when model membranes were used as substrate. This opposite modulatory effect on biological membranes and model membranes is discussed with respect to different mechanisms the interaction of the regulatory peptides with the enzyme molecules and the substrate vesicles.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1065-6995(03)00176-8 | DOI Listing |
Anal Chim Acta
February 2025
Chemical and Petroleum Engineering Department, Sharif University of Technology, Tehran, Iran.
Background: Bee venom consists of more than 50 % melittin (MLT), which has anti-cancer, anti-inflammatory, and antimicrobial properties. Bee venom also contains toxic components such as phospholipase A2 (PLA2) and hyaluronidase (HYA), which cause allergic reactions, so the toxic components must be removed to use MLT. In previous studies, analytical methods were used to separate MLT.
View Article and Find Full Text PDFFront Immunol
January 2025
Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Rheumatoid arthritis (RA), a condition characterized by joint deterioration through the action of matrix metalloproteinases (MMPs), is prevalent worldwide. Bee venom (BV) has traditionally been used in Chinese medicine for pain, arthritis, rheumatism, skin diseases, etc. BV is enriched with active substances, notably melittin and phospholipase A2 (PLA2), offering significant therapeutic potential.
View Article and Find Full Text PDFToxicon
December 2024
Department of Immunology, Medical Research Institute, Colombo, Sri Lanka.
Apis dorsata stings are amongst the most frequent insect-stings in Sri Lanka. A. dorsata venom consists of a mixture of components including PLA, melittin, hyaluronidase and apamin.
View Article and Find Full Text PDFPharmaceuticals (Basel)
September 2024
Biohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Apitoxin therapy (BVT-bee venom therapy) is an emerging complementary treatment utilizing bee venom for various medical conditions. This review explores the potential and therapeutic mechanisms of bee venom, focusing on its chemical composition and the methods for its extraction and purification to enhance safety while maintaining bioactivity. Bee venom contains amphipathic peptides such as melittin and apamin, enzymes like phospholipase A2, and bioamines including histamine and catecholamines, contributing to its pleiotropic effects.
View Article and Find Full Text PDFBiomed Pharmacother
October 2024
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China; Hebei Medical University, Shijiazhuang, China. Electronic address:
As the research on cancer-related treatment deepens, integrating traditional therapies with emerging interventions reveals new therapeutic possibilities. Melittin and phospholipase A2, the primary anti-cancer components of bee venom, are currently gaining increasing attention. This article reviews the various formulations of melittin in cancer therapy and its potential applications in clinical treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!